Our results showed that the novel PD-L1-containing MSLN targeting vaccine was able to activate a MSLN and PD-L1-specific T cell immune responses in immunized mice, inhibit the growth of MSLN+ and PD-L1+ tumor cells. The gene discussed is MSLN; the disease is neoplasm.